Stoke Therapeutics appoints EY as new auditor

Stoke Therapeutics changed its independent auditor, dismissing KPMG LLP and appointing Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.

Accepted by SEC EDGAR 03/27/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Stoke Therapeutics changed its independent auditor, dismissing KPMG LLP and appointing Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.

The company states that KPMG’s audit reports for 2024 and 2025 contained no adverse or qualified opinions, and there were no disagreements or reportable events under SEC rules through March 23, 2026. KPMG provided a letter to the SEC agreeing with these disclosures, which is included as an exhibit.

8-K Event Classification

2 items: 4.01, 9.01

2 items

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What auditor change did Stoke Therapeutics (STOK) disclose in this 8-K?

Stoke Therapeutics dismissed KPMG LLP as its independent auditor and appointed Ernst & Young LLP for the fiscal year ending December 31, 2026. This means EY will audit the company’s 2026 financial statements instead of KPMG.

Were there any disagreements between Stoke Therapeutics (STOK) and KPMG?

The company reports no disagreements with KPMG on accounting principles, financial disclosure, or audit procedures through March 23, 2026. It also states there were no reportable events under Item 304(a)(1)(v) of Regulation S-K during this period.

How did KPMG’s prior audit opinions for Stoke Therapeutics (STOK) look?

KPMG’s reports on Stoke Therapeutics’ consolidated financial statements for the years ended December 31, 2024 and 2025 did not contain adverse opinions, disclaimers of opinion, or qualifications related to uncertainty, audit scope, or accounting principles, according to the disclosure.

Did Stoke Therapeutics (STOK) consult EY before making the auditor change?

The company states that during its two most recent fiscal years and through March 23, 2026, it did not consult EY on matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K, such as specific accounting treatments or audit opinions.

What document did KPMG provide regarding Stoke Therapeutics’ auditor change?

KPMG furnished a letter dated March 27, 2026, addressed to the SEC, indicating its position on Stoke Therapeutics’ disclosures about the auditor change. This letter is filed as Exhibit 16.1 and forms part of the company’s current report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001623526 0001623526 2026-03-23 2026-03-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2026

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38938		47-1144582
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
45 Wiggins Ave
Bedford, Massachusetts				01730
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		STOK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01 Changes in Registrant’s Certifying Accountants.

(a) Dismissal of Previous Independent Registered Public Accounting Firm

On March 23, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Stoke Therapeutics, Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.

The reports of KPMG on the consolidated financial statements of the Company as of and for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

During the fiscal years ended December 31, 2025 and 2024, and during the interim period through March 23, 2026, there were (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K between the Company and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, any of which, if not resolved to KPMG’s satisfaction, would have caused KPMG to make reference thereto in their reports, and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

The Company provided KPMG with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that KPMG furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein and, if not, stating the respects in which it does not agree. A copy of such letter provided by KPMG, dated March 27, 2026, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) Appointment of New Independent Registered Public Accounting Firm

On March 23, 2026, the Audit Committee approved the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. During the Company’s two most recent fiscal years ended December 31, 2025 and 2024, and during the interim period through March 23, 2026, neither the Company nor anyone acting on its behalf consulted with EY regarding any of the matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
16.1		Letter from KPMG LLP, dated March 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						STOKE THERAPEUTICS, INC.
Date: March 27, 2026				By:		/s/ Thomas Leggett
						Thomas Leggett
						Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-16.1 EX-16.1 1.9 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB